Department of Paediatrics, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Department of Nephrology, The Key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Heart Fail Rev. 2023 Sep;28(5):1211-1220. doi: 10.1007/s10741-023-10304-7. Epub 2023 Mar 13.
Heart failure is a complex clinical syndrome, whose signs and symptoms are caused by functional or structural impairment of ventricular filling or ejection of blood. Due to the interaction among anticancer treatment, patients' cardiovascular background, including coexisting cardiovascular diseases and risk factors, and cancer itself, cancer patients develop heart failure. Some drugs for cancer treatment may cause heart failure directly through cardiotoxicity or indirectly through other mechanisms. Heart failure in turn may make patients lose effective anticancer treatment, thus affecting the prognosis of cancer. Some epidemiological and experimental evidence shows that there is a further interaction between cancer and heart failure. Here, we compared the cardio-oncology recommendations among heart failure patients of the recent 2022 American guidelines, 2021 European guidelines, and 2022 European guidelines. Each guideline acknowledges the role of multidisciplinary (cardio-oncology) discussion before and during scheduled anticancer therapy.
心力衰竭是一种复杂的临床综合征，其体征和症状是由心室充盈或射血的功能或结构损害引起的。由于抗癌治疗、患者的心血管背景（包括并存的心血管疾病和危险因素）以及癌症本身之间的相互作用，癌症患者会发生心力衰竭。一些用于癌症治疗的药物可能通过心脏毒性直接或通过其他机制间接导致心力衰竭。心力衰竭反过来可能使患者失去有效的抗癌治疗，从而影响癌症的预后。一些流行病学和实验证据表明，癌症和心力衰竭之间存在进一步的相互作用。在这里，我们比较了 2022 年美国指南、2021 年欧洲指南和 2022 年欧洲指南中心力衰竭患者的肿瘤心脏病学建议。每个指南都承认在计划进行抗癌治疗之前和期间进行多学科（肿瘤心脏病学）讨论的作用。
